Economy

Enrollment begins for Sanofi and GSK’s Phase 3 efficacy trial of Covid-19 vaccine candidate in Nepal

KATHMANDU: Sanofi and GSK received approval for their Phase 3 clinical study in Nepal to assess the safety, efficacy and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate. The International Vaccine Institute (IVI), an international organization dedicated to the discovery, development and delivery of safe, effective and affordable vaccines, will...

Pages: 1 327 328 329 330 331 387